Litcius/Paper detail

Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial

Akihito Kawazoe, Shota Fukuoka, Yoshiaki Nakamura, Yasutoshi Kuboki, Masashi Wakabayashi, Shogo Nomura, Yuichi Mikamoto, Hikari Shima, Noriko Fujishiro, Tsukiko Higuchi, Akihiro Sato, Takeshi Kuwata, Kohei Shitara

2020The Lancet Oncology270 citationsDOI

Topics & Concepts

LenvatinibPembrolizumabMedicineInternal medicineResponse Evaluation Criteria in Solid TumorsClinical endpointOncologyCabozantinibCancerPhases of clinical researchClinical trialGastroenterologyImmunotherapyThyroid cancerGastric Cancer Management and OutcomesCancer Immunotherapy and BiomarkersGastrointestinal Tumor Research and Treatment
Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial | Litcius